Article
Validation of the Double-Hit Gene Expression Signature (DLBCL90) in an Independent Cohort of Patients with Diffuse Large B-Cell Lymphoma of Germinal Center Origin.
The Journal of molecular diagnostics : JMD - 1 May 2021
Nguyen Ha, Perry Anamarija, Skrabek Pamela, Nasr Michel, Herrera Alex F, Bedell Victoria, Murata-Collins Joyce, Pillai Raju, Xu Minlin, Chen Lu, Chan Wing C, Weisenburger Dennis D, Scott David W, Song Joo Y
Abstract excerpt
The prognosis of diffuse large B-cell lymphoma (DLBCL) has been associated with clinical parameters, cell of origin, and various genetic aberrations. Recently, a NanoString gene expression assay (DLBCL90) was developed, which identifies DLBCL cases with an outcome similar to those with double- or triple-hit DLBCL with both MYC and BCL2 rearrangements. This study validates the predictive ability of the DLBCL90...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
